Akebia Therapeutics Framtida tillväxt
Future kriterier kontrolleras 0/6
Akebia Therapeutics förväntas öka vinsten och intäkterna med 23.4% och 4% per år respektive medan EPS förväntas växa med 23.5% per år.
Viktig information
23.4%
Tillväxttakt i vinsten
23.53%
Tillväxttakt för EPS
| Biotechs vinsttillväxt | 27.1% |
| Intäkternas tillväxttakt | 4.0% |
| Framtida avkastning på eget kapital | n/a |
| Bevakning av analytiker | Low |
| Senast uppdaterad | 17 Aug 2026 |
Senaste uppdateringarna om framtida tillväxt
Recent updates
Uppdatering av berättelse • Aug 07
AKBA: Expanded Kidney Pipeline And Patent Extensions Will Support Future Profitability
Akebia Therapeutics has seen its analyst price target raised from $3.00 to $4.00, with analysts pointing to updated assumptions around discount rates, revenue growth, profit margins, and future P/E expectations to support the change. What’s in the News for Akebia Therapeutics Akebia Therapeutics initiated a Phase 2 open-label basket trial of ebribafusp for rare complement mediated kidney diseases including IgA nephropathy, lupus nephritis, and C3 glomerulopathy.
Uppdatering av berättelse • Jun 24
Market Anger vs. Valuation Disconnect
The current low price is driven by market fury over management's failure to handle an expected product transition. By reacting emotionally to a temporary operational blunder, the market has created a massive disconnect between Akebia's current price and its true intrinsic value.
Uppdatering av berättelse • Jun 22
AKBA: Extended Kidney Patent Protection Will Support Future Upside Potential
Analysts have adjusted their price target for Akebia Therapeutics to $6.00, citing updated assumptions about the discount rate, revenue growth, profit margin, and future P/E, which together support this revised valuation view. What’s in the News for Akebia Therapeutics Akebia Therapeutics was removed from the S&P Biotechnology Select Industry Index, reflecting a change in index membership based on that provider’s criteria.Uppdatering av berättelse • Jun 05
AKBA: Kidney Pipeline Expansion And Share Authorization Increase Will Support Upside Potential
Analysts have maintained their $6.00 price target for Akebia Therapeutics, citing only minor updates in their underlying assumptions on discount rate, revenue growth, profit margins, and future P/E as the reason for no change in the headline number. What's in the News Akebia Therapeutics plans to seek shareholder approval to amend its Ninth Amended and Restated Certificate of Incorporation to increase authorized capital stock to 525,000,000 shares and authorized common stock to 500,000,000 shares.Uppdatering av berättelse • May 19
AKBA: Kidney Pipeline Advances Will Offset Renal Channel Inventory Adjustments
Narrative Update on Akebia Therapeutics Analysts have trimmed their price target on Akebia Therapeutics stock by $1 to $4, citing a new US Renal Care dosing protocol that they say reduced channel inventory by about $4.5M to $5.0M and contributed to Vafseo revenue recognized in Q4 coming in $5M to $6M lower than they had expected. Analyst Commentary Bullish analysts are framing the recent price target trim as a fine tuning of expectations rather than a shift in the core thesis on Akebia Therapeutics.Analysartikel • May 11
Here's What Analysts Are Forecasting For Akebia Therapeutics, Inc. (NASDAQ:AKBA) After Its First-Quarter Results
There's been a major selloff in Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) shares in the week since it released its...Uppdatering av berättelse • May 03
AKBA: Kidney Pipeline Progress Will Drive Future Upside Despite Inventory Headwinds
Narrative Update on Akebia Therapeutics Analysts have reduced Akebia Therapeutics' price target by $1 to $4, citing updated expectations for Vafseo revenue after a new US Renal Care dosing protocol and related channel inventory adjustments. Analyst Commentary Bullish analysts appear focused on how recent pricing and dosing updates feed into the long term opportunity for Vafseo, even as they recalibrate near term expectations.Uppdatering av berättelse • Apr 19
AKBA: Renal Dosing Reset And Inventory Shift Will Support Future Profitability
Akebia Therapeutics' consensus analyst price target has shifted lower, with moves such as a cut from $5 to $4 at BTIG and a $2 reduction at Piper Sandler as analysts factor in recent Vafseo revenue shortfalls tied to US Renal Care's updated dosing protocol and related channel inventory effects. Analyst Commentary Bearish analysts are reassessing Akebia Therapeutics after Vafseo revenue recognized in Q4 came in at about US$5m to US$6m, which they link to a new US Renal Care protocol and an estimated US$4.5m to US$5m decrease in channel inventory.
Uppdatering av berättelse • Apr 05
AKBA: Phase 2 Kidney Trial Will Offset Dosing Protocol Revenue Reset
Akebia Therapeutics' Street price targets have been trimmed by analysts, with one firm moving from $5 to $4 as they factor in lower than expected Q4 Vafseo revenue tied to a new US Renal Care dosing protocol and related channel inventory reductions. Analyst Commentary Bullish Takeaways Bullish analysts still see upside potential even after trimming price targets.Uppdatering av berättelse • Mar 22
AKBA: Renal Care Dosing Reset Will Support Stronger Long Term Profitability
Akebia Therapeutics' consensus analyst price target has moved lower to $4 from $5, as analysts factor in recent updates on Vafseo revenue recognition tied to US Renal Care dosing protocols and related channel inventory adjustments. Analyst Commentary Bearish analysts are framing the lower $4 price target as a reflection of execution risk around the Vafseo launch, especially after the new US Renal Care dosing protocol affected how much revenue could be recognized in the quarter.Ny berättelse • Mar 13
Vafseo and the Future of Renal Anemia Treatment – Akebia’s Vision for a $5B Kidney Disease Portfolio
Renal anemia is one of the most common complications of chronic kidney disease (CKD). As kidney function declines, the production of erythropoietin (EPO) decreases, resulting in reduced stimulation of red blood cell production in the bone marrow and the development of anemia.Uppdatering av berättelse • Mar 07
AKBA: Phase 2 Kidney Disease Trial And Dosing Reset Will Drive Upside
Narrative Update Akebia Therapeutics' consensus analyst price target has shifted from about $5 to roughly $4.40, as analysts factor in the recent US Renal Care dosing protocol change and its impact on Vafseo channel inventory and recognized Q4 revenue. Analyst Commentary Recent research updates reflect a mixed read on Akebia Therapeutics, with targets adjusted to roughly US$4, as analysts factor in the new US Renal Care dosing protocol and its effect on Vafseo revenue recognition in Q4.Uppdatering av berättelse • Feb 21
AKBA: Rare Kidney Pipeline Progress Will Support Stronger Long Term Profitability
Analysts have reduced their Akebia Therapeutics price target by $3, citing a lower fair value estimate, a higher discount rate, and a shift to expectations of declining revenue growth. This is partly offset by a slightly stronger profit margin outlook and a lower assumed future P/E multiple.Uppdatering av berättelse • Feb 07
AKBA: Phase 2 Kidney Disease Pipeline Progress Will Drive Substantial Upside
Analysts have trimmed their fair value estimate for Akebia Therapeutics from US$5.40 to US$5.00, citing updated assumptions for growth, profitability and a higher future P/E multiple reflected in recent Street research, including the lowered Piper Sandler price target. Analyst Commentary Recent research around Akebia Therapeutics has focused on how updated growth and profitability assumptions feed into valuation, including the trimmed fair value estimate and a reset price target.Uppdatering av berättelse • Jan 24
AKBA: Rare Kidney Disease Pipeline Progress Will Drive Future Upside
Analysts now set their price target for Akebia Therapeutics at US$6.00, unchanged from the prior US$6.00. This reflects updated assumptions around discount rate, revenue growth, profit margin, and future P/E that largely offset each other in their valuation work.Uppdatering av berättelse • Jan 10
AKBA: Rare Kidney Pipeline And Anemia Data Will Support Future Upside
Analysts have adjusted their price target on Akebia Therapeutics to US$6.00 from US$6.00, reflecting updated assumptions around the discount rate, expected revenue growth, profit margin and a slightly higher future P/E multiple. What's in the News Akebia dosed the first patient in a Phase 2 randomized, double blind, placebo controlled trial of praliciguat for biopsy confirmed focal segmental glomerulosclerosis.Uppdatering av berättelse • Dec 26
AKBA: Rare Kidney Pipeline Progress Will Drive Future Share Upside
Analysts have nudged their price target for Akebia Therapeutics slightly higher to 6.00 dollars per share from 6.00 dollars previously, reflecting modestly improved long term assumptions around revenue growth, profit margins, and the companys risk profile. What's in the News Akebia has initiated Phase 2 clinical development of praliciguat for focal segmental glomerulosclerosis, triggering an expected 1.0 million dollar regulatory milestone payment to Cyclerion when the first patient is dosed, anticipated in 2026 (Key Developments).Uppdatering av berättelse • Dec 12
AKBA: Rare Kidney Franchise Will Drive Future Share Upside Despite Higher Risk
Analysts have reduced their fair value estimate for Akebia Therapeutics from 10.00 dollars to 6.00 dollars, citing a higher perceived risk profile. This is reflected in an increased discount rate and a lower future earnings multiple, even as long term revenue growth and margin expectations edge higher.Uppdatering av berättelse • Nov 28
AKBA: European Partnership And Clinical Data Will Drive Substantial Upside
Analysts have slightly lowered their price target for Akebia Therapeutics from $5.50 to $5.40, citing updated financial forecasts, as well as expectations for improved profit margins and revenue growth. What's in the News Akebia Therapeutics and Medice amended their License Agreement and granted Medice the right to manufacture Vafseo tablets for anemia in chronic kidney disease patients in Europe.Uppdatering av berättelse • Nov 13
AKBA: Broad U.S. Launch In 2025 Will Drive Upside Potential
Analysts have lowered their price target for Akebia Therapeutics from $6.80 to $5.50, citing moderated expectations for revenue growth and profitability. What's in the News Akebia Therapeutics presented a post-hoc win odds analysis from the Phase 3 INNO2VATE trials of vadadustat, showing favorable effects of Vafseo compared to darbepoetin alfa on death or hospitalization in dialysis patients.Analysartikel • Nov 04
Revenues Working Against Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Share Price Following 25% Dive
Unfortunately for some shareholders, the Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) share price has dived 25% in the...Uppdatering av berättelse • Oct 30
AKBA: Expanding Access in Dialysis Settings Will Drive Future Upside
Analysts have adjusted their price target for Akebia Therapeutics from $7.40 to $6.80. They cite slight shifts in projected valuation metrics and underlying financial assumptions.Analysartikel • Aug 10
Is Akebia Therapeutics (NASDAQ:AKBA) A Risky Investment?
NasdaqCM:AKBA 1 Year Share Price vs Fair Value Explore Akebia Therapeutics's Fair Values from the Community and select...Analysartikel • Jun 18
There's No Escaping Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Muted Revenues Despite A 34% Share Price Rise
Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) shareholders would be excited to see that the share price has had a great...Analysartikel • May 10
Akebia Therapeutics, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Investors in Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) had a good week, as its shares rose 4.1% to close at US$2.55...Analysartikel • May 04
There's No Escaping Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Muted Revenues Despite A 38% Share Price Rise
Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) shareholders would be excited to see that the share price has had a great...
Ny berättelse • Apr 28
Vafseo And VALOR Study Will Open New Treatment Markets
Early success of Vafseo and reimbursement coverage expansion likely to drive strong revenue growth and market access.Analysartikel • Mar 20
Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Price Is Right But Growth Is Lacking After Shares Rocket 33%
Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) shares have continued their recent momentum with a 33% gain in the last month...Analysartikel • Mar 16
Earnings Update: Here's Why Analysts Just Lifted Their Akebia Therapeutics, Inc. (NASDAQ:AKBA) Price Target To US$7.83
Shareholders of Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) will be pleased this week, given that the stock price is up...Analysartikel • Jan 22
Improved Revenues Required Before Akebia Therapeutics, Inc. (NASDAQ:AKBA) Stock's 30% Jump Looks Justified
Despite an already strong run, Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) shares have been powering on, with a gain of...Prognoser för vinst- och omsättningstillväxt
| Datum | Intäkter | Intäkter | Fritt kassaflöde | Kassaflöde från rörelsen | Genomsnittligt Antal analytiker |
|---|---|---|---|---|---|
| 12/31/2028 | 178 | -41 | -33 | -47 | 4 |
| 12/31/2027 | 140 | -85 | -59 | -60 | 5 |
| 12/31/2026 | 197 | -41 | -37 | -39 | 5 |
| 6/30/2026 | 219 | -30 | 29 | 42 | N/A |
| 3/31/2026 | 232 | -21 | 52 | 60 | N/A |
| 12/31/2025 | 236 | -5 | 60 | 68 | N/A |
| 9/30/2025 | 225 | -16 | 32 | 32 | N/A |
| 6/30/2025 | 204 | -36 | -3 | -2 | N/A |
| 3/31/2025 | 185 | -45 | -35 | -35 | N/A |
| 12/31/2024 | 160 | -69 | -41 | -41 | N/A |
| 9/30/2024 | 170 | -46 | -39 | -39 | N/A |
| 6/30/2024 | 174 | -40 | -39 | -39 | N/A |
| 3/31/2024 | 187 | -43 | -25 | -25 | N/A |
| 12/31/2023 | 195 | -52 | -23 | -23 | N/A |
| 9/30/2023 | 194 | -59 | -76 | -76 | N/A |
| 6/30/2023 | 201 | -98 | -35 | -35 | N/A |
| 3/31/2023 | 271 | -58 | -69 | -69 | N/A |
| 12/31/2022 | 292 | -94 | -73 | -73 | N/A |
| 9/30/2022 | 294 | -158 | -81 | -81 | N/A |
| 6/30/2022 | 294 | -163 | -171 | -171 | N/A |
| 3/31/2022 | 221 | -276 | -204 | -204 | N/A |
| 12/31/2021 | 212 | -282 | -253 | -253 | N/A |
| 9/30/2021 | 211 | -299 | -221 | -221 | N/A |
| 6/30/2021 | 222 | -300 | -192 | -192 | N/A |
| 3/31/2021 | 259 | -392 | -92 | -92 | N/A |
| 12/31/2020 | 295 | -385 | -111 | -110 | N/A |
| 9/30/2020 | 308 | -391 | -172 | -172 | N/A |
| 6/30/2020 | 340 | -386 | -136 | -134 | N/A |
| 3/31/2020 | 351 | -268 | N/A | -209 | N/A |
| 12/31/2019 | 335 | -280 | N/A | -257 | N/A |
| 9/30/2019 | 325 | -245 | N/A | -239 | N/A |
| 6/30/2019 | 286 | -217 | N/A | -262 | N/A |
| 3/31/2019 | 234 | -193 | N/A | -215 | N/A |
| 12/31/2018 | 208 | -144 | N/A | -97 | N/A |
| 9/30/2018 | 238 | -68 | N/A | -40 | N/A |
| 6/30/2018 | 227 | -65 | N/A | -82 | N/A |
| 3/31/2018 | 206 | -53 | N/A | -67 | N/A |
| 12/31/2017 | 181 | -74 | N/A | -56 | N/A |
| 9/30/2017 | 92 | -127 | N/A | 56 | N/A |
| 6/30/2017 | 51 | -140 | N/A | 82 | N/A |
| 3/31/2017 | 22 | -154 | N/A | 31 | N/A |
| 12/31/2016 | 2 | -136 | N/A | 58 | N/A |
| 9/30/2016 | N/A | -118 | N/A | -61 | N/A |
| 6/30/2016 | N/A | -101 | N/A | -41 | N/A |
| 3/31/2016 | N/A | -76 | N/A | -27 | N/A |
| 12/31/2015 | N/A | -61 | N/A | -52 | N/A |
Analytiker Framtid Tillväxt Prognoser
Intäkter kontra sparande: AKBA förväntas förbli olönsam under de kommande 3 åren.
Resultat vs marknad: AKBA förväntas förbli olönsam under de kommande 3 åren.
Höga tillväxtresultat: AKBA förväntas förbli olönsam under de kommande 3 åren.
Intäkt vs marknad: AKBA s intäkter ( 4% per år) förväntas växa långsammare än marknaden för US ( 13% per år).
Hög tillväxtintäkter: AKBA s intäkter ( 4% per år) förväntas växa långsammare än 20% per år.
Tillväxtprognoser för vinst per aktie
Framtida avkastning på eget kapital
Framtida ROE: Otillräcklig data för att avgöra om AKBA s avkastning på eget kapital förväntas bli hög om tre år
Upptäck tillväxtföretag
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/08/17 14:43 |
| Aktiekurs vid dagens slut | 2026/08/17 00:00 |
| Intäkter | 2026/06/30 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Akebia Therapeutics, Inc. bevakas av 17 analytiker. 5 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Julian Harrison | BTIG |
| Michael King | Citizens JMP Securities, LLC |
| Jason Butler | Citizens JMP Securities, LLC |